Tisinone: Remedy for Hereditary tyrosinemia type 1

The FDA-approved medicine Enhertu is recommended to treat patients with unresectable or metastatic HER2-positive breast cancer. Enhertu contains Trastuzumab Deruxtecan as an active ingredient with inactive ingredients L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, and sucrose. This medicine is supplied in single-use vials in 100 mg to administer intravenously. The recommended dosage of Enhertu 100 mg is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity. Trastuzumab Deruxtecan is a cytotoxic drug supplied as a white to yellowish-white lyophilized powder in a single-dose vial for reconstitution and further dilution. One should store this medicine at 2ºC to 8ºC (36ºF to 46ºF) in the original carton to protect it from light until reconstitution. One should not freeze the medicine. And one should not shake the reconstituted or diluted solution.
There are several certified Enhertu suppliers in India, and organizations like Indian Pharma Network help you connect potential suppliers of such generic medicines. For more details call us on 18008891064.
Tweet